Search results for "hormonal treatment"

showing 2 items of 2 documents

Male breast cancer.

2010

Male breast cancer (MaleBC) is a rare disease, accounting for <1% of all male tumors. During the last few years, there has been an increase in the incidence of this disease, along with the increase in female breast cancer (FBC). Little is known about the etiology of MaleBC: hormonal, environmental and genetic factors have been reported to be involved in its pathogenesis. Major risk factors include clinical disorders carrying hormonal imbalances, radiation exposure and, in particular, a positive family history (FH) for BC, the latter suggestive of genetic susceptibility. Rare mutations in high-penetrance genes (BRCA1 and BRCA2) confer a high risk of BC development; low-penetrance gene mutati…

CounselingMalemedicine.medical_specialtymedicine.medical_treatmentchemotherapyHyperestrogenismsurvivalBreast Neoplasms MalesurgeryBreast cancerRisk Factorspolycyclic compoundsmedicineHumansgeneticsFamily historyskin and connective tissue diseaseshormonal treatmentneoplasmsradiotherapyGynecologytherapybusiness.industryCarcinomaCancerHematologybacterial infections and mycosesmedicine.diseasePrognosisMale breast cancergenetics; hormonal treatment; male breast cancer; survival; local recurrence; radiotherapy; therapy; surgery; chemotherapyRadiation therapyOncologyMale breast cancerbacteriaFemaleBreast diseaselocal recurrencemedicine.symptombusinessAlgorithmsRare disease
researchProduct

APOPTOSIS RATE IN CUMULUS CELLS AS POSSIBLE MOLECULAR BIOMARKER FOR OOCYTE COMPETENCE.

2017

Several lines of evidence showed that apoptosis rate of cumulus cells in oocytes derived by assisted reproductive technologies could be used as an indicator of fertilizing gamete quality. Aim of the study was to investigate the effects of three different ovarian stimulation protocols on the biological and clinical outcome in hyporesponder patients. Collected data showed a higher significant rate of DNA fragmentation index (DFI) in U group (patients treated with Highly Purified human Menopausal Gonadotrophin) than in P group (treated with recombinant human Follicle Stimulating Hormone (r-hFSH) combined with recombinant human Luteinizing Hormone (r-hLH)). Both groups R (treated with r-hFSH al…

Oocyte competence Granulosa cells DNA fragmentation Hormonal treatment Poor responderSettore BIO/06 - Anatomia Comparata E Citologia
researchProduct